WELCURE

Welcure Drugs & Pharmaceuticals Share Price

₹8.07 0.00 (0.00%)

22 Nov, 2024 07:54

SIP TrendupStart SIP in WELCURE

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 4.94%
  • Over 3 Month + 10.1%
  • Over 6 Month + 42.33%
  • Over 1 Year + 99.26%
SIP Lightning

Smart Investing Starts Here Start SIP with Welcure Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Welcure Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Welcure Drugs & Pharmaceuticals Financials

Welcure Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹8.07
0 (0%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹7.35
  • 50 Day
  • ₹6.49
  • 100 Day
  • ₹5.78
  • 200 Day
  • ₹5.22

Resistance and Support

8.07 Pivot Speed
  • R3 8.07
  • R2 8.07
  • R1 8.07
  • S1 8.07
  • S2 8.07
  • S3 8.07

What's your outlook on Welcure Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Welcure Drugs & Pharms. has an operating revenue of Rs. 24.71 Cr. on a trailing 12-month basis. An annual revenue de-growth of -63% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -12% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 26 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 85 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Welcure Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results (Revised)
2024-10-21 Others
2024-08-14 Quarterly Results
2024-06-10 Others Inter alia, 1. To augment of financial resources of the company, 2. To increase in authorised share capital of the company and 3. To shift branch office of the company.
2024-05-30 Audited Results (Revised)

Welcure Drugs & Pharmaceuticals F&O

Welcure Drugs & Pharmaceuticals Shareholding Pattern

0%
93.55%
6.45%

About Welcure Drugs & Pharmaceuticals

  • NSE Symbol
  • WELCURE
  • BSE Symbol
  • 524661
  • Managing Director & CFO
  • Mr. Altaf Hussain Shah
  • ISIN
  • INE331C01017

Similar Stocks to Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals FAQs

Welcure Drugs & Pharmaceuticals share price is ₹8 As on 22 November, 2024 | 07:40

The Market Cap of Welcure Drugs & Pharmaceuticals is ₹10.9 Cr As on 22 November, 2024 | 07:40

The P/E ratio of Welcure Drugs & Pharmaceuticals is 7.5 As on 22 November, 2024 | 07:40

The PB ratio of Welcure Drugs & Pharmaceuticals is 8.1 As on 22 November, 2024 | 07:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23